Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL

• DOI: 10.1200/jco.23.00546
• Publication Date: 2023-10-26T20:00:15Z
• Authors: Matthias Stelljes; Simon Raffel; Nael Alakel; Ralph Wäsch; Mustafa Kondakci; Sebastian Scholl; Andreas Rank; Mathias Hänel; Bernd Spriewald; Maher Hanoun; Sonja Martin; Katjana Schwab; Hubert Serve; Lena Reiser; Julian Knaden; Heike Pfeifer; Julia Marx; Tim Sauer; Wolfgang E. Berdel; Georg Lenz; Monika Brüggemann; Nicola Gökbuget; Klaus Wethmar
• Keywords: Clinical endpoint; Minimal Residual Disease; Salvage therapy

Despite recent advances in adapting the intensity of treatment for older patients with ALL, current protocols are associated high rates early deaths, treatment-related toxicity, and dismal prognosis. We evaluated inotuzumab ozogamicin dexamethasone (Dex) as induction therapy ALL within German Multicenter Study Group Adult (GMALL).